Researchers unlock how progesterone increases breast cancer risk

January 18, 2011, Michigan State University

Researchers have identified how the hormones progesterone and estrogen interact to increase cell growth in normal mammary cells and mammary cancers, a novel finding that may explain why postmenopausal women receiving hormone replacement therapy with estrogen plus progestin are at increased risk of breast cancer.

The discovery that both and progesterone must be present for the increased production of the protein amphiregulin, which binds to mammary cells and promotes cell growth, could lead to new treatment methods for the disease, said Sandra Haslam, director of Michigan State University's Breast Cancer and the Environment Research Center and lead researcher on the project.

The study, funded by the Department of Defense's Breast Cancer Research Program and published in Hormones and Cancer, looked at why progesterone combined with estrogen may contribute to increased breast cancer risk. In the study, researchers used both the native , progesterone, and a , progestin – obtaining the same results.

The finding might help explain earlier results from the groundbreaking Women's Health Initiative showing the risk of breast cancer is significantly greater for who received with combined estrogen plus progestin compared to women receiving estrogen alone.

"Also, breast cancers that develop in women receiving estrogen plus progestin are more invasive and deadlier," Haslam said. "What is the progestin doing to increase the risk of tumor growth?"

Along with co-investigator Anastasia Kariagina, a colleague in the College of Human Medicine and Department of Physiology, Haslam identified the amphiregulin and its receptor as one potential culprit.

"Amphiregulin – acting through its receptor, epidermal growth factor receptor – along with progesterone leads to the activation of intracellular pathways that regulate cell growth," Haslam said. "When activated, this promotes normal cell growth and the growth of tumors."

The study was performed in rats because breast cancers in rats contain receptors for estrogen and progesterone – similar to the human breast – and tumor growth is hormone-dependent, as are the majority of human breast cancers. The research team also confirmed the same phenomenon in human breast cancer cell cultures.

In addition, the research team found that Iressa, a cancer drug that blocks the epidermal growth factor receptor, effectively stopped the proliferation caused by amphiregulin. While those studies were done only in cell cultures and not on tumors growing in animals, the results are promising, Haslam said.

"The results indicate that the interactions between estrogen, progesterone and epidermal growth factor receptor pathways may be considered relevant targets for the treatment of hormone-dependent breast cancers," she said. "This may be especially important in premenopausal breast cancer because women produce their own estrogen and .

"A combined approach of inhibiting both the hormones and the epidermal growth factor receptor may be beneficial for some women in treating hormone-dependent ."

More information: The article can be viewed at www.springerlink.com/content/2 … 5833472/fulltext.pdf

Related Stories

Recommended for you

Stem cell vaccine immunizes lab mice against multiple cancers

February 15, 2018
Stanford University researchers report that injecting mice with inactivated induced pluripotent stem cells (iPSCs) launched a strong immune response against breast, lung, and skin cancers. The vaccine also prevented relapses ...

Induced pluripotent stem cells could serve as cancer vaccine, researchers say

February 15, 2018
Induced pluripotent stem cells, or iPS cells, are a keystone of regenerative medicine. Outside the body, they can be coaxed to become many different types of cells and tissues that can help repair damage due to trauma or ...

Team paves the way to the use of immunotherapy to treat aggressive colon tumors

February 15, 2018
In a short space of time, immunotherapy against cancer cells has become a powerful approach to treat cancers such as melanoma and lung cancer. However, to date, most colon tumours appeared to be unresponsive to this kind ...

Can our genes help predict how women respond to ovarian cancer treatment?

February 15, 2018
Research has identified gene variants that play a significant role in how women with ovarian cancer process chemotherapy.

First comparison of common breast cancer tests finds varied accuracy of predictions

February 15, 2018
Commercially-available prognostic breast cancer tests show significant variation in their abilities to predict disease recurrence, according to a study led by Queen Mary University of London of nearly 800 postmenopausal women.

Catching up to brain cancer: Researchers develop accurate model of how aggressive cancer cells move and spread

February 15, 2018
A brief chat at a Faculty Senate meeting put two University of Delaware researchers onto an idea that could be of great value to cancer researchers.

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

_eslea_ate
not rated yet Jan 22, 2011
x
_eslea_ate
not rated yet Jan 22, 2011
So no comparison to supplementing actual progesterone, only seeing what was already there would do? Seems sloppy & incomplete. Synthetic progestogens are NOT the same as actual progesterone. It's like comparing a ford rustbucket to a new Mercedes SLS. there's only superficial similarities. What type of estrogen was used? By what route? The type & method of introduction can skew the results too.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.